Affordable Access

deepdyve-link
Publisher Website

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.

Authors
  • Glazer, Evan S1
  • Piccirillo, Mauro
  • Albino, Vittorio
  • Di Giacomo, Raimondo
  • Palaia, Raffaele
  • Mastro, Angelo A
  • Beneduce, Gerardo
  • Castello, Giuseppe
  • De Rosa, Vincenzo
  • Petrillo, Antonella
  • Ascierto, Paolo A
  • Curley, Steven A
  • Izzo, Francesco
  • 1 Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
May 01, 2010
Volume
28
Issue
13
Pages
2220–2226
Identifiers
DOI: 10.1200/JCO.2009.26.7765
PMID: 20351325
Source
Medline
License
Unknown

Abstract

Pegylated ADI is a promising drug that capitalizes on a significant enzymatic deficiency in HCC. It is safe, well tolerated, and may benefit patients with unresectable HCC.

Report this publication

Statistics

Seen <100 times